Drug intelligence / Profile preview

AC2592

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Peptides
Administration: Subcutaneous

Overview

AC2592 is a synthetic peptide that acts as a glucagon-like peptide-1 receptor (GLP-1R) agonist. It was administered via continuous subcutaneous infusion using a pump, with dosing based on patient body weight. The drug was initially developed by Amylin Pharmaceuticals and later investigated by AstraZeneca for the treatment of chronic congestive heart failure, particularly for patients with New York Heart Association (NYHA) class III or IV heart failure who were not suitable for transplantation.

Other names: Glucagon-like peptide-1(Amylin)

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on AC2592.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC2592.

Explore the full profile